國泰君安：諾誠健華ICP-488國內進度領先，慢病管線加速推進

金融界

2024/10/12

　　國泰君安研報指出，諾誠健華(9969.HK)Tyk2(ICP-488)治療中重度斑塊狀銀屑病二期臨牀數據優異。ICP-488國內進度領先，展示出不輸同類競品潛力，血液瘤管線進展順利，慢病管線加速推進。公司創新管線推進順利，拓展自免和實體瘤治療。①Tafasitamab中國r/rDLBCL 的BLA已受理，預計25年獲批。②預計ICP332（TYK2-JH1）在2024Q4開啓AD的III期以及開啓白癜風II/III期；美國首例患者已給藥。③ICP-723 (NTRK)的晚期實體瘤註冊臨牀試驗加速推進，預計2025Q1遞交NDA。⑤ICP-189聯合伏美替尼仍在進展中，預計2024年底取得 PoC。

關注同花順財經（ths518），獲取更多機會

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2474004612"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2474004612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2474004612?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-10-12 15:06","share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","id":"2474004612","market":"sg","top_or_hot":-1,"title":"國泰君安：諾誠健華ICP-488國內進度領先，慢病管線加速推進","media":"金融界","content":"<html><body><div>\n<p>　　<a href=\"https://laohu8.com/S/601211\">國泰君安</a>研報指出，<a href=\"https://laohu8.com/S/688428\">諾誠健華</a>(9969.HK)Tyk2(ICP-488)治療中重度斑塊狀銀屑病二期臨牀數據優異。ICP-488國內進度領先，展示出不輸同類競品潛力，血液瘤管線進展順利，慢病管線加速推進。公司創新管線推進順利，拓展自免和實體瘤治療。①Tafasitamab中國r/rDLBCL 的BLA已受理，預計25年獲批。②預計ICP332（TYK2-JH1）在2024Q4開啓AD的III期以及開啓白癜風II/III期；美國首例患者已給藥。③ICP-723 (NTRK)的晚期實體瘤註冊臨牀試驗加速推進，預計2025Q1遞交NDA。⑤ICP-189聯合伏美替尼仍在進展中，預計2024年底取得 PoC。</p>\n<p><strong>關注<a href=\"https://laohu8.com/S/300033\">同花順</a>財經（ths518），獲取更多機會</strong></p>\n<span></span>\n</div></body></html>","source":"tonghuashun","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>國泰君安：諾誠健華ICP-488國內進度領先，慢病管線加速推進</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n國泰君安：諾誠健華ICP-488國內進度領先，慢病管線加速推進\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界</strong><span class=\"h-time small\">2024-10-12 15:06</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p>　　<a href=\"https://laohu8.com/S/601211\">國泰君安</a>研報指出，<a href=\"https://laohu8.com/S/688428\">諾誠健華</a>(9969.HK)Tyk2(ICP-488)治療中重度斑塊狀銀屑病二期臨牀數據優異。ICP-488國內進度領先，展示出不輸同類競品潛力，血液瘤管線進展順利，慢病管線加速推進。公司創新管線推進順利，拓展自免和實體瘤治療。①Tafasitamab中國r/rDLBCL 的BLA已受理，預計25年獲批。②預計ICP332（TYK2-JH1）在2024Q4開啓AD的III期以及開啓白癜風II/III期；美國首例患者已給藥。③ICP-723 (NTRK)的晚期實體瘤註冊臨牀試驗加速推進，預計2025Q1遞交NDA。⑤ICP-189聯合伏美替尼仍在進展中，預計2024年底取得 PoC。</p>\n<p><strong>關注<a href=\"https://laohu8.com/S/300033\">同花順</a>財經（ths518），獲取更多機會</strong></p>\n<span></span>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://stock.10jqka.com.cn/hks/20241012/c662358328.shtml\">金融界</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海國資改革","start_time":0,"source_url":"http://stock.10jqka.com.cn/hks/20241012/c662358328.shtml","article_id":"2474004612","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474004612","pubTimestamp":1728716817,"columns":[],"sourceInfo":{"source_id":"tonghuashun","name":"同花顺"},"weMediaInfo":null,"summary":"國泰君安研報指出，諾誠健華(9969.HK)Tyk2(ICP-488)治療中重度斑塊狀銀屑病二期臨牀數據優異。ICP-488國內進度領先，展示出不輸同類競品潛力，血液瘤管線進展順利，慢病管線加速推進。公司 ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601211":"国泰海通","688428":"诺诚健华","BK0184":"上海国资改革","BK0028":"国家队","BK0239":"医药制造","BK6512":"房地产股","BK0276":"资本市场","BK0201":"可转债","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK6004":"海运"},"translate_title":"Guotai Junan: InnoCare ICP-488 leads the domestic progress, and the chronic disease pipeline is accelerating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601211":1,"688428":1,"5I4.SI":1},"content_text":"國泰君安研報指出，諾誠健華(9969.HK)Tyk2(ICP-488)治療中重度斑塊狀銀屑病二期臨牀數據優異。ICP-488國內進度領先，展示出不輸同類競品潛力，血液瘤管線進展順利，慢病管線加速推進。公司創新管線推進順利，拓展自免和實體瘤治療。①Tafasitamab中國r/rDLBCL 的BLA已受理，預計25年獲批。②預計ICP332（TYK2-JH1）在2024Q4開啓AD的III期以及開啓白癜風II/III期；美國首例患者已給藥。③ICP-723 (NTRK)的晚期實體瘤註冊臨牀試驗加速推進，預計2025Q1遞交NDA。⑤ICP-189聯合伏美替尼仍在進展中，預計2024年底取得 PoC。\n關注同花順財經（ths518），獲取更多機會","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}